⌘K
t
| Date | 4 Jun 2024 |
| Time | 07:00:10 |
| Category | Miscellaneous |
| ID | 9402Q |
4 June 2024
Incanthera plc
("Incanthera" the "Company")
AQSE Webinar Presentation
'Aquis Leading Lights: Meet the Company of the Year 2024 Nominees'
Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology, is pleased to announce that it will be presenting at an Aquis Stock Exchange Webinar, for Small Cap Awards 2024 Nominees.
Chairman, Tim McCarthy, will be presenting an overview of Incanthera's growth and progression from the company's flotation onto Aquis in February 2020, to the most recent commercial updates, leading to their Nominee as Aquis Company of the Year 2024.
The presentation, which will not contain any inside information, will be made available on the day on the company's website, www.incanthera.com.
Aquis Stock Exchange makes a point of championing entrepreneurship, investment and growth. This webinar will provide an overview of AQSE and give investors and advisors the chance to hear from and interact with the senior management of the nominees for the Aquis Award.
For further information on the event, the Nominees and to Register to see Incanthera's presentation, please click on the link below:
RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.
For further information please contact:
|
Incanthera plc
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Suzanne Brocks, Head of Communications |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
|
|
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney |
+44 (0) 20 3650 3650/51 |
Notes to Editors
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc